European Journal of Pediatrics

, Volume 162, Issue 11, pp 776–780 | Cite as

Quantitative calcaneal ultrasound parameters and bone mineral density at final height in girls treated with depot gonadotrophin-releasing hormone agonist for central precocious puberty or idiopathic short stature

  • Simone Kapteijns-van Kordelaar
  • Kees NoordamEmail author
  • Barto Otten
  • Joop van den Bergh
Original Paper


To evaluate the effect of gonadotrophin-releasing hormone (GnRH) agonist treatment on bone quality at final height, we studied girls with central precocious puberty (CPP) and with idiopathic short stature (ISS). A total of 25 Caucasian girls were included: group A ( n =14) with idiopathic CPP (mean age at start 7.4 years) and group B ( n =11) with ISS (mean age at start 11.7 years). Treatment duration was 3.8 and 1.7 years respectively. The quantitative ultrasound parameters (QUS) broadband ultrasound attenuation (BUA) and speed of sound (SOS) were measured at the calcaneus (UBIS 3000 device). Lumbar spine bone mineral density (BMD; L2–L4) was measured by dual energy X-ray absorptiometry (DXA) (Hologic QDR1000). Measurements were performed at final height and expressed as Z-scores corrected for bone age. Mean Z-scores of QUS parameters, areal BMD and volumetric BMD (BMDvol) were above −1 in both groups (group A: BUA Z-score −0.21, SOS Z-score −0.29, BMD Z-score 0.02, BMDvol Z-score 0.05, group B: BUA Z-score −0.93, SOS Z-score −0.40, BMD Z-score −0.86, BMDvol Z-score −0.68), although mean Z-scores of BUA and areal BMD in group B were significantly different from zero ( P =0.03 and P =0.02 respectively). Mean Z-score BMDvol was not significantly different from zero ( P =0.05), we found no significant difference between the groups for BMDvol ( P =0.13). Conclusion:although quantitative ultrasound parameters parameters and bone mineral density were normal in girls with central precocious puberty at final height after gonadotrophin-releasing hormone agonist treatment, mean Z-score for broadband ultrasound attenuation and areal bone mineral density were significantly different from zero and mean Z-score for volumetric bone mineral density was (just) not significantly different from zero in idiopathic short stature girls with normal puberty treated with gonadotrophin-releasing hormone agonists. Therefore we cannot say that this treatment is safe in these girls with regard to bone health.


Bone mineral density Central precocious puberty Gonadotrophin-releasing hormone agonist Idiopathic short stature Quantitative ultrasound parameters 



bone mineral density


volumetric bone mineral density


body mass index


broadband ultrasound attenuation


central precocious puberty


dual X-ray absorptiometry


gonadotrophin-releasing hormone


idiopathic short stature


quantitative ultrasound


standard deviation score


speed of sound


  1. 1.
    Antoniazzi F, Bertoldo F, Zamboni G, Valentini R, Sirpresi S, Cavallo L, Adami S, Tato L (1995) Bone mineral metabolism in girls with precocious puberty during gonadotrophin-releasing hormone agonist treatment. Eur J Endocrinol 133: 412–417PubMedGoogle Scholar
  2. 2.
    Bauer DC, Gluer CC, Cauley JA, Vogt TM, Ensrud KE, Genant HK, Black DM (1997) Broadband ultrasound attenuation predicts fractures strongly and independently of densitometry in older women. A prospective study of the Osteoporotic Fractures Research Group. Arch Intern Med 157: 629–634PubMedGoogle Scholar
  3. 3.
    Bertelloni S, Baroncelli GI, Sorrentino MC, Perri G, Saggesse G (1998) Effect of central precocious puberty and gonadotropin-releasing hormone analogue treatment on peak bone mass and final height in females. Eur J Pediatr 157: 363–367CrossRefPubMedGoogle Scholar
  4. 4.
    Boot AM, De Muinck Keizer-Schrama SMPF, Pols HAP, Krenning EP, Drop SL (1998) Bone mineral density and body composition before and during treatment with gonadotropin-releasing hormone agonist in children with central precocious and early puberty. J Clin Endocrinol Metab 83: 370–373PubMedGoogle Scholar
  5. 5.
    Bonjour J-P, Theintz G, Buchs B, Slosman D, Rizzoli R (1991) Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence. J Clin Endocrinol Metab 73: 555–563Google Scholar
  6. 6.
    Carel J-C, Chaussain J-L (1999) Gonadotropin releasing hormone agonist treatment for central precocious puberty. Horm Res 51[Suppl 3]: 64–69Google Scholar
  7. 7.
    Cassio A, Cacciari E, Balsamo A, Bal M, Tassinari D (1999) Randomised trial of LHRH analogue treatment on final height in girls with onset of puberty aged 7.5–8.5 years. Arch Dis Child 81: 329–332PubMedGoogle Scholar
  8. 8.
    Del Rio L, Carrascosa F, Pons F, Gusinye M, Yeste D, Domenech FM (1994) Bone mineral density of the lumbar spine in white mediterranean Spanish children and adolescents: changes related to age, sex and puberty. Pediatr Res 35: 362–366Google Scholar
  9. 9.
    Fournier B, Chappard C, Roux C, Berger G, Laugier P (1997) Quantitative ultrasound imaging at the calcaneus using an automatic region of interest. Osteoporos Int 7: 363–369PubMedGoogle Scholar
  10. 10.
    Fournier P-E, Rizolli R, Slosman D-O, Theintz G, Bonjour J-P (1997) Asynchrony between the rates of standing height gain and bone mass accumulation during puberty. Osteoporos Int 7: 525–532PubMedGoogle Scholar
  11. 11.
    Frank GR (1995) The role of estrogen in pubertal skeleton physiology: epiphyseal maturation and mineralization of the skeleton. Acta Paediatr 84: 627–630PubMedGoogle Scholar
  12. 12.
    Fredriks AM, van Buuren S, Burgmeijer RJ, Meulmeester JF, Brugman E, Roede MJ, Verloove-Vanhorick SP, Wit JM (2000) Continuing positive secular growth change in the Netherlands 1955–1997. Pediatr Res 47: 316–323PubMedGoogle Scholar
  13. 13.
    Gluer CC, Blake G, Lu Y, Blunt BA, Jerges M, Genant HK (1995) Accurate assessment of precision errors: how to measure the reproducibility of bone densitometry techniques. Osteoporos Int 5: 262–270PubMedGoogle Scholar
  14. 14.
    Greulich WW, Pyle SI (1995) Radiographic atlas of skeletal development of the hand and the wrist, 2nd edn. Stanford University Press, CaliforniaGoogle Scholar
  15. 15.
    Heger S, Partsch C-J, Sippell WG (1999) Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function. J Clin Endocrinol Metab 84: 4583–4590PubMedGoogle Scholar
  16. 16.
    Kleerekoper M, Villanueva AR, Stanciu J, Rao DS, Parfitt AM (1985) The role of three-dimensional trabecular micro-structure in the pathogenesis of vertebral compression fractures. Calcif Tissue Int 37: 594–597PubMedGoogle Scholar
  17. 17.
    Klein KO, Barnes KM, Jones JV, Feuillan PP, Cutler GB Jr (2001) Increased final height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Health experience. J Clin Endocrinol Metab 86: 4711–4716PubMedGoogle Scholar
  18. 18.
    Kröger H, Kotaniemi A, Kröger L, Alhava E (1993) Development of bone mass and bone density of the spine and femoral neck- a prospective study of 65 children and adolescents. Bone Miner 23: 171–182PubMedGoogle Scholar
  19. 19.
    Laugier P, Fournier B, Berger G (1996) Ultrasound parametric imaging of the calcaneus: in vivo results with a new device. Calcif Tissue Int 58:326–331CrossRefPubMedGoogle Scholar
  20. 20.
    Lindner D, Job JC, Chaussain JL (1993) Failure to improve final height prediction in short-stature pubertal adolescents by inhibiting puberty with luteinizing hormone-releasing hormone analogue. Eur J Pediatr 152: 393–396PubMedGoogle Scholar
  21. 21.
    Neely EK, Bachrach LK, Hintz RL, Habiby RL, Slemenda CW, Feezle L, Pescovitz OH (1995) Bone mineral density during treatment of central precocious puberty. J Pediatr 127: 819–822PubMedGoogle Scholar
  22. 22.
    Oostdijk W, Rikken B, Schreuder S, Otten B, Odink R, Rouwe C, Jansen M, Gerver WJ, Waelkens J, Drop S (1996) Final height in central precocious puberty after long term treatment with a slow release GnRH agonist. Arch Dis Child 75: 292–297PubMedGoogle Scholar
  23. 23.
    Partsch C-J, Heger S, Sippell WG, and the German Decapeptyl Study Group (2000) Treatment of central precocious puberty: lessons from 15 years prospective trial. J Pediatr Endocrinol Metab 13[Suppl 1]: 747–758Google Scholar
  24. 24.
    Sagesse G, Bertelloni S, Baroncelli GI, Battini R, Franchi G (1993) Reduction of bone density: an effect of gonadotropin releasing hormone analogue treatment in central precocious puberty. Eur J Pediatr 152: 717–720PubMedGoogle Scholar
  25. 25.
    Sagesse G, Bertelloni S, Baroncelli GI (1997) Sex steroids and the acquisition of bone mass. Horm Res 48[Suppl 5]: 65–71Google Scholar
  26. 26.
    Sagesse G, Baroncelli GI, Bertelloni S (2002) Puberty and bone development. Best Pract Res Clin Endocrinol Metab 16: 53–64CrossRefPubMedGoogle Scholar
  27. 27.
    Stasiowksa B, Vannelli S, Benso L (1994) Final height in sexually precocious puberty girls after therapy with an intranasal analogue of gonadotrophin-releasing hormone (Busereline). Horm Res 42: 81–85PubMedGoogle Scholar
  28. 28.
    Takahashi Y, Minamitani K, Kobayashi Y, Minagawa M, Yasuda T, Niimi H (1996) Spinal and femoral bone mass accumulation during normal adolescence: comparison with female patients with sexual precocity and with hypogonadism. J Clin Endocrinol Metab 81: 1248–1253Google Scholar
  29. 29.
    Theintz G, Buchs B, Rizzoli R, Slosman D, Clavien H, Sizonenko PC, Bonjour J-P (1992) Longitudinal monitoring of bone mass accumulation in healthy adolescents: evidence for marked reduction after 16 years of age at levels of lumbar spine and femoral neck in female subjects. J Clin Endocrinol Metab 75: 1060–1065Google Scholar
  30. 30.
    Van Coeverden SCCM, De Ridder CM, Roos JC, Van 't Hof MA, Netelenbos JC, Delemarre-van de Waal HA (2001) Pubertal maturation characteristics and the rate of bone mass development longitudinally toward menarche. J Bone Min Res 16: 774–781Google Scholar
  31. 31.
    Van den Bergh JP, Noordam C, Ozyilmaz A, Hermus AR, Smals AG, Otten BJ (2000) Calcaneal ultrasound imaging in healthy children and adolescents: relation of the ultrasound parameters BUA and SOS to age, body weight, height, foot dimensions and pubertal stage. Osteoporos Int 11: 967–976PubMedGoogle Scholar
  32. 32.
    Verrotti A, Chiarelli F, Montanaro AF, Morgese G (1995) Bone mineral content in girls with precocious puberty treated with gonadotropin-releasing hormone analog. Gynecol Endocrinol 9: 277–281PubMedGoogle Scholar
  33. 33.
    Yanovski JA, Rose SR, Municchi G, Pescotvitz OH, Hill SC, Cassorla FG, Cutler GB (2003) Treatment with a luteinizing hormone-releasing hormone agonist in adolescents with short stature. N Eng J Med 348: 908–917CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  • Simone Kapteijns-van Kordelaar
    • 1
  • Kees Noordam
    • 1
    Email author
  • Barto Otten
    • 1
  • Joop van den Bergh
    • 2
  1. 1.Department of Paediatric EndocrinologyA University Medical CentreNijmegen The Netherlands
  2. 2.Department of Internal MedicineSint MaartensgasthuisVenlo The Netherlands

Personalised recommendations